Of note, our results converge with a recent case report using the GLP-1 receptor agonist semaglutide in a patient with obesity and cocaine abuse, which documented parallel reductions in weight and cocaine craving over 12 weeks. This evidence concerns the gene GLP1R and obesity disorder.